Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer



Status:Recruiting
Conditions:Prostate Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:September 14, 2018
End Date:July 29, 2019
Contact:Gary Barnette
Email:gbarnette@verupharma.com
Phone:919-426-3611

Use our guide to learn which trials are right for you!

Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer

Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily
dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the
vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate
cancer

This study is a multicenter, randomized, double-blind, placebo controlled, dose finding study
of VERU-944 to treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on
ADT. The study will have four arms with 30 subjects per arm. The subjects participating in
the study will have advanced prostate cancer and will be undergoing androgen deprivation
therapy (ADT) with a luteinizing hormone releasing hormone (LHRH) therapy (agonist or
antagonist) for at least the three months prior to randomization and be experiencing regular
moderate to severe hot flashes while on ADT. Subjects will all continue to receive ADT and
will be randomized to receive, for the first four days, a loading dose followed by daily
doses of placebo or VERU-944 (10 mg, 50 mg or 100 mg) orally for a total period of 12 weeks.

Inclusion Criteria

1. Be over 18 years of age;

2. Be able to communicate effectively with the study personnel;

3. Have histologically confirmed prostate cancer;

4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months
prior to randomization;

5. Be continued on an LHRH agonist or LHRH antagonist throughout this study;

6. Have experienced hot flashes for at least one month prior to study entry;

7. Have moderate or severe vasomotor symptoms (hot flashes) (defined as a minimum of 4
moderate to severe hot flashes per day or 12 per week at baseline);

8. ECOG performance status of 0 to 2

9. Be willing to uses electronic data capture for the relevant medical events

• Must be at least 80% compliant during the screening period

10. Subjects must agree to use acceptable methods of contraception:

- If their female partners are pregnant or lactating, acceptable methods of
contraception from the time of the first administration of study medication until
6 months following administration of the last dose of study medication must be
used. Acceptable methods are: Condom used with spermicidal
foam/gel/film/cream/suppository. If the subject has undergone surgical
sterilization (vasectomy with documentation of azospermia), a condom with
spermicidal foam/gel/film/cream/suppository should be used.

- If the male subject's partner could become pregnant, use acceptable methods of
contraception from the time of the first administration of study medication until
6 months following administration of the last dose of study medication.
Acceptable methods of contraception are as follows: Condom with spermicidal
foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical
sterilization (vasectomy with documentation of azospermia) and a barrier method
{condom used with spermicidal foam/gel/film/cream/suppository}, the female
partner uses oral contraceptives (combination estrogen/progesterone pills),
injectable progesterone or subdermal implants and a barrier method (condom used
with spermicidal foam/gel/film/cream/suppository).

- If the female partner has undergone documented tubal ligation (female
sterilization), a barrier method (condom used with spermicidal
foam/gel/film/cream/suppository) should also be used.

- If the female partner has undergone documented placement of an intrauterine
device (IUD) or intrauterine system (IUS), a barrier method (condom with
spermicidal foam/gel/film/cream/suppository) should also be used.

11. Subject is willing to comply with the requirements of the protocol through the end of
the study.

Exclusion Criteria

1. Have a serum total testosterone concentration > 50 ng/dL at screening;

2. Known hypersensitivity or allergy to estrogen or estrogen like drugs;

3. Any disease or condition (medical or surgical) which might compromise the hematologic,
cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central
nervous system; or other conditions that may interfere with the absorption,
distribution, metabolism or excretion of study drug, or would place the subject at
increased risk;

4. Subjects with a personal history of abnormal blood clotting or thrombotic disease,
including venous or arterial thrombotic events such as a history of stroke, deep vein
thrombosis (DVT), and/or pulmonary embolus (PE);

5. Any subjects, as determined by a central laboratory, that have a:

- Factor V Leiden gene mutation

- Prothrombin gene mutation

6. Uncontrolled symptomatic congestive heart failure (NYHA Class III - IV), unstable
angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation;

7. History of MI

8. The presence of consistently abnormal laboratory values which are considered
clinically significant. In addition, any subject with liver enzymes (ALT or AST) above
2 times the upper limit of normal, total bilirubin above 2 times the upper limit of
normal, or serum creatinine above 1.5 times the upper limit of normal will NOT be
admitted to the study;

9. Received an investigational drug within a period of 90 days prior to enrollment in the
study;

10. Received the study medication (VERU-944) previously;

11. Have previously taken within 6 months prior to screening or are currently taking
diethylstilbestrol, other estrogens;

12. Currently taking gabapentin, estrogen, diethylstilbestrol, medroxyprogesterone
acetate, clomiphene, selective serotonin reuptake inhibitors (SSRIs), other treatments
for hot flashes

13. Recent hospitalization for more than 24 hours (within 30 days of screening);

14. Recent surgery (within 30 days of screening);

15. Have been previously diagnosed or treated for active cancer (other than prostate
cancer or non-melanoma skin cancer) within the previous five years;

16. Have a BMI >40.
We found this trial at
19
sites
Towson, Maryland 21204
Phone: 410-825-5454
?
mi
from
Towson, MD
Click here to add this to my saved trials
Bala-Cynwyd, Pennsylvania 19004
Phone: 610-667-0485
?
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Brick, New Jersey 08724
Phone: 732-840-4300
?
mi
from
Brick, NJ
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Phone: 208-415-1749
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Dallas, Texas 75231
Phone: 214-580-1391
?
mi
from
Dallas, TX
Click here to add this to my saved trials
7777 Forest Lane
Dallas, Texas 75230
Phone: 972-566-3000
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80211
Phone: 303-762-7155
?
mi
from
Denver, CO
Click here to add this to my saved trials
3650 Northwest 82nd Avenue
Doral, Florida 33166
Phone: 305-898-7888
?
mi
from
Doral, FL
Click here to add this to my saved trials
Edison, New Jersey 08837
Phone: 732-494-9400
?
mi
from
Edison, NJ
Click here to add this to my saved trials
Elmont, New York 11003
Phone: 516-328-8775
?
mi
from
Elmont, NY
Click here to add this to my saved trials
Garden City, New York 11530
Phone: 516-746-2190
?
mi
from
Garden City, NY
Click here to add this to my saved trials
Golden, Colorado 80401
Phone: 303-985-2550
?
mi
from
Golden, CO
Click here to add this to my saved trials
Jeffersonville, Indiana 47130
Phone: 812-206-8161
?
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Los Angeles, California 90048
Phone: 310-854-9898
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
243 N Rd
Poughkeepsie, New York 12601
(845) 471-9410
Phone: 845-437-5010
Premier Medical Group of the Hudson Valley Premier Medical Group offers comprehensive, integrated care providing...
?
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
San Antonio, Texas 78229
Phone: 210-617-4116
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Bernardino, California 92404
Phone: 909-881-0555
?
mi
from
San Bernardino, CA
Click here to add this to my saved trials
Syracuse, New York 13210
Phone: 315-478-4185
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
Virginia Beach, Virginia 23462
Phone: 757-452-3461
?
mi
from
Virginia Beach, VA
Click here to add this to my saved trials